Press release -

US FDA 510(k) Clearance for Luer-Jack® Slip syringe

ConceptoMed AS received FDA 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the first size of the Luer-Jack® syringe.

I am very pleased to receive FDA 510(k) market clearance for our first size of the Luer-Jack® Slip syringe. The FDA 510(k) market clearance represents another important milestone in our global company strategy and will open up potential of establishing a commercial presence of the Luer-Jack® in the world’s largest single US healthcare market”, said Christian Mide, M.D., CEO and founder of ConceptoMed.

About Luer-Jack®

Luer-Jack® is a user-friendly syringe, which will become an important contribution to procedure quality and aseptic procedures when handling medical connections – simply by its one-handed disconnection capability. Luer-Jack® is delivered in a simple to use and uniquely designed packaging – the Steri-Tilt.

Health authorities and medical professionals now have the option of implementing a medical device with an integrated and user-friendly one-handed aseptic disconnection technique as part of the medical device itself.

A key element of a next-generation medical syringe could become the development away from using two hands during disconnections.

Luer-Jack® Slip syringes are already CE marked and sold by distributors in Europe.

For more information, please visit www.luerjack.com and/or contact:

Christian Mide, CEO - christian.mide@conceptomed.com +47 95 100 720
Martinsen, Director QA & Reg. - marit.martinsen@conceptomed.com +47 905 146 90
Ann-Christine Jungmar, CCO - ann-christine.jungmar@conceptomed.com +46 708 71 46 76

Related links

Topics

  • Business enterprise

Categories

  • healtcare worker
  • needlestick
  • safety syringes
  • medical procedures
  • injection
  • medical device
  • syringes and needles market

ConceptoMed AS is a ISO 13485 certified, ambitious medtech company serving the global market with innovative product categories and unique proprietary technology. We create smart medtech systems that empower healthcare professionals and improve patient care. Excellence through simplicity is our code. We are brave, curious and dedicated. We simply care.

Based in Norway, the team is continuously meeting milestones and expanding its activities for international growth. For more information on the company and career opportunities, see www.conceptomed.com and www.luerjack.com. Follow us on MyNewsdesk and LinkedIn.

Luer-Jack® is a registered trademark owned by ConceptoMed AS. The Luer-Jack® technology is widely patent protected throughout the world, currently with almost 50 patents (granted and pending) from 8 patent families.

Contacts

Christian Mide

Press contact CEO +47 95 100720

Related content

US Patent issued for Luer-Jack®

On the 10th of May 2016, the United States Patent and Trademark office issued an official document granting the US patent for Luer-Jack. The US Luer-Jack patent is an important part of the families of similar filed applications in all important markets world wide, and is a fundamental member of the Luer-Jack patent family.

Luer-Jack high-volume production agreement with AB Euroform MediPharm, Sweden

On the 28th of October 2016, ConceptoMed and AB Euroform MediPharm entered into an agreement for high-volume capacity manufacturing for Luer-Jack. Euroform MediPharm is a ISO 13485 certified long-term partner within development and production of polymer products for world class customers in Pharmaceutical and Medical Technology industries.

LuerJack Lock - US FDA 510(k) cleared

ConceptoMed AS has received FDA 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the LuerJack Slip syringes and the first LuerJack Lock 10ml syringe.

Chinese Patent issued for LuerJack

On the 14th of February 2017, the Chinese Patent and Trademark office issued an official document granting the Chinese patent for LuerJack. ConceptoMed’s strategy to protect our intellectual property rights (IPR) remains unchanged and strong. Along with other markets already protected, such as Europe, the US, Australia and Mexico, protection in Asia is now following.